These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37694398)

  • 21. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):901-11. PubMed ID: 25186657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries.
    Marijam A; Schuerman L; Izurieta P; Pereira P; Van Oorschot D; Mehta S; Ota MO; Standaert B
    Hum Vaccin Immunother; 2022 Dec; 18(7):2135916. PubMed ID: 36507685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009.
    Elston JW; Santaniello-Newton A; Meigh JA; Harmer D; Allgar V; Allison T; Richardson G; Meigh R; Palmer SR; Barlow G
    Epidemiol Infect; 2012 Jul; 140(7):1252-66. PubMed ID: 22040368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Shirley M
    Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation.
    Dagan R
    Expert Rev Vaccines; 2019 Jun; 18(6):641-661. PubMed ID: 31230486
    [No Abstract]   [Full Text] [Related]  

  • 27. Increasing influenza and pneumococcal vaccine uptake in the elderly: study protocol for the multi-methods prospective intervention study Vaccination60.
    Betsch C; Rossmann C; Pletz MW; Vollmar HC; Freytag A; Wichmann O; Hanke R; Hanke W; Heinemeier D; Schmid P; Eitze S; Weber W; Reinhardt A; Küpke NK; Forstner C; Fleischmann-Struzek C; Mikolajetz A; Römhild J; Neufeind J; Rieck T; Suchecka K; Reinhart K
    BMC Public Health; 2018 Jul; 18(1):885. PubMed ID: 30012141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
    Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
    Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
    Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
    Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland.
    Deb A; Guggisberg P; Mutschler T; Owusu-Edusei K; Bencina G; Johnson KD; Ignacio T; Mathijssen DAR; Qendri V
    Expert Rev Vaccines; 2022 May; 21(5):711-722. PubMed ID: 35220875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence.
    Niederman MS; Folaranmi T; Buchwald UK; Musey L; Cripps AW; Johnson KD
    Expert Rev Vaccines; 2021 Mar; 20(3):243-256. PubMed ID: 33478306
    [No Abstract]   [Full Text] [Related]  

  • 36. Pneumococcal vaccination-A literature review and practice guideline update.
    El-Beyrouty C; Buckler R; Mitchell M; Phillips S; Groome S
    Pharmacotherapy; 2022 Sep; 42(9):724-740. PubMed ID: 35876213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries.
    Cohen R; Cohen JF; Chalumeau M; Levy C
    Expert Rev Vaccines; 2017 Jun; 16(6):625-640. PubMed ID: 28409537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.
    Singleton RJ; Hennessy TW; Bulkow LR; Hammitt LL; Zulz T; Hurlburt DA; Butler JC; Rudolph K; Parkinson A
    JAMA; 2007 Apr; 297(16):1784-92. PubMed ID: 17456820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the epidemiology and prevention of
    Feldman C; Anderson R
    F1000Res; 2020; 9():. PubMed ID: 32411353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.